Bezsonov Evgeny, Chernyi Nikita, Saruhanyan Mane, Shimchenko Dariia, Bondar Nikolai, Gavrilova Darina, Baig Mirza S, Malogolovkin Alexander
Laboratory of Molecular Virology, First Moscow State Medical University (Sechenov University), Moscow 119435, Russia.
Department of Biology and General Genetics, First Moscow State Medical University (Sechenov University), Moscow 105043, Russia.
Int J Mol Sci. 2025 Jul 19;26(14):6950. doi: 10.3390/ijms26146950.
Atherosclerosis is a complex disease characterized by pathological thickening of the arterial intima. The mechanisms underlying the induction and progression of atherosclerosis are convoluted and remain under active investigation, with key components such as lipid accumulation and local inflammation being identified. Several risk factors (e.g., metabolic disorders, genetic background, diet, infections) have been shown to exacerbate disease progression, but their roles as clinically relevant markers remain to be established. Despite the growing body of evidence on the molecular pathogenesis of atherosclerosis, there is no effective preventive treatment against the development of this disease. In this review, we focus on gene targets for gene therapy as a novel potential approach to cure and prevent atherosclerosis. We critically review recent research demonstrating the therapeutic potential of viral vector-based (adeno-associated virus (AAV) and lentivirus) gene therapy for the treatment of atherosclerosis. We also summarize alternative gene targets and approaches (e.g., non-coding RNA (ncRNA), micro RNA (miRNA), small interfering RNA (siRNA), antisense oligonucleotide (ASO), CRISPR/Cas9) that aim to limit disease progression. We highlight the importance of local inflammation in the pathogenesis of atherosclerosis and propose gene targets with anti-inflammatory activity to inhibit the pathological inflammatory response. In addition, we provide perspectives on the future development of gene therapeutics and their potential applications. We anticipate that recent advances in gene therapy will help to identify new and effective targets to prevent atherosclerosis.
动脉粥样硬化是一种以动脉内膜病理性增厚为特征的复杂疾病。动脉粥样硬化发生和发展的潜在机制错综复杂,仍在积极研究中,脂质蓄积和局部炎症等关键因素已被确定。已证实多种危险因素(如代谢紊乱、遗传背景、饮食、感染)会加剧疾病进展,但其作为临床相关标志物的作用仍有待确定。尽管关于动脉粥样硬化分子发病机制的证据越来越多,但尚无针对该疾病发展的有效预防性治疗方法。在本综述中,我们聚焦于基因治疗的基因靶点,这是一种治疗和预防动脉粥样硬化的新型潜在方法。我们批判性地回顾了近期研究,这些研究证明了基于病毒载体(腺相关病毒(AAV)和慢病毒)的基因治疗对动脉粥样硬化的治疗潜力。我们还总结了旨在限制疾病进展的其他基因靶点和方法(如非编码RNA(ncRNA)、微小RNA(miRNA)、小干扰RNA(siRNA)、反义寡核苷酸(ASO)、CRISPR/Cas9)。我们强调局部炎症在动脉粥样硬化发病机制中的重要性,并提出具有抗炎活性的基因靶点以抑制病理性炎症反应。此外,我们还展望了基因治疗的未来发展及其潜在应用。我们预计基因治疗的最新进展将有助于确定预防动脉粥样硬化的新的有效靶点。
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2020-1-9
Cochrane Database Syst Rev. 2017-12-22
Cochrane Database Syst Rev. 2018-2-6
Psychopharmacol Bull. 2024-7-8
Cochrane Database Syst Rev. 2012-12-12
Cochrane Database Syst Rev. 2024-2-27
Cochrane Database Syst Rev. 2024-6-4
Am J Physiol Heart Circ Physiol. 2025-4-1
Handb Clin Neurol. 2024
Atherosclerosis. 2024-11
Nat Cardiovasc Res. 2023-11
Front Cell Dev Biol. 2024-8-12
Ann Med Surg (Lond). 2024-5-15
BMC Cardiovasc Disord. 2024-7-30